TCL Archive Progression-free survival as a primary endpoint for drug approval requires prospective planning, FDA’s Pazdur says. May 7, 2004
TCL Archive Interim Funding: Noncompeting Renewals Reduced By 4 Percent, Competing Current Plus 7 Percent January 8, 1982
TCL Archive FDA Consider Regulation of CME Programs Paid for By Drug Companies; Goal To Limit Promotion January 3, 1992
